Application of holistic liquid chromatography-high resolution mass spectrometry based urinary metabolomics for prostate cancer detection and biomarker discovery by Zhang, T. et al.
  
 
 
 
 
Zhang, T., Watson, D.G., Wang, L., Abbas, M., Murdoch, L., Bashford, L., 
Ahmad, I., Lam, N.-Y., Ng, A.C.F., and Leung, H.Y. (2013) Application of 
holistic liquid chromatography-high resolution mass spectrometry based urinary 
metabolomics for prostate cancer detection and biomarker discovery. PLoS ONE, 
8 (6). e65880. ISSN 1932-6203 
 
 
Copyright © 2013 The Authors 
 
 
 
http://eprints.gla.ac.uk/84277 
 
 
 
 
Deposited on: 12 August 2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Application of Holistic Liquid Chromatography-High
Resolution Mass Spectrometry Based Urinary
Metabolomics for Prostate Cancer Detection and
Biomarker Discovery
Tong Zhang1*, David G. Watson1., Lijie Wang1, Muhammad Abbas1, Laura Murdoch4, Lisa Bashford3,
Imran Ahmad2,3, Nga-Yee Lam5, Anthony C. F. Ng5, Hing Y. Leung2,3.
1 Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, Scotland, United Kingdom, 2Department of Urology, Gartnavel General Hospital, Glasgow,
Scotland, United Kingdom, 3 The Beatson Institute for Cancer Research, Glasgow, Scotland, United Kingdom, 4Glasgow Clinical Research Facility, Glasgow, Scotland,
United Kingdom, 5Department of Urology, Chinese University of Hong Kong, Hong Kong
Abstract
Human exhibit wide variations in their metabolic profiles because of differences in genetic factors, diet and lifestyle.
Therefore in order to detect metabolic differences between individuals robust analytical methods are required. A protocol
was produced based on the use of Liquid Chromatography- High Resolution Mass Spectrometry (LC-HRMS) in combination
with orthogonal Hydrophilic Interaction (HILIC) and Reversed Phase (RP) liquid chromatography methods for the analysis of
the urinary metabolome, which was then evaluated as a diagnostic tool for prostate cancer (a common but highly
heterogeneous condition). The LC-HRMS method was found to be robust and exhibited excellent repeatability for retention
times (,61%), and mass accuracy (,61 ppm). Based on normalised data (against creatinine levels, osmolality or MS total
useful signals/MSTUS) coupled with supervised multivariate analysis using Orthogonal Partial Least Square-Discriminant
Analysis (OPLS-DA), we were able to discriminate urine samples from men with or without prostate cancer with R2Y(cum)
.0.9. In addition, using the receiver operator characteristics (ROC) test, the area under curve (AUC) for the combination of
the four best characterised biomarker compounds was 0.896. The four biomarker compounds were also found to differ
significantly (P,0.05) between an independent patient cohort and controls. This is the first time such a rigorous test has
been applied to this type of model. If validated, the established protocol provides a robust approach with a potentially wide
application to metabolite profiling of human biofluids in health and disease.
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Introduction
Prostate cancer is the most prevalent cancer in the male
population in Western countries. Prostate cancer is highly
heterogeneous with highly variable clinical outcomes: indolent
disease tends not to progress even over many years while
aggressive (high grade) disease often progresses quickly to result
in metastases which inevitably result in premature death. In
addition, there is a significant limitation in specificity with the
current practice using serum prostate specific antigen (PSA)
measurement as a diagnostic tool. Hence, there is an urgent need
for better diagnostic and prognostic tests for prostate cancer.
Evolving evidence points to the input of highly versatile
metabolic pathways in fuelling carcinogenesis [1] thus detailed
analysis of the tumour-associated metabolome may reveal novel
biomarkers [2,3]. Analysis of urine, plasma and/or tissue samples
can be performed with Nuclear Magnetic Resonance (NMR)
spectroscopy or/and Mass Spectrometry (MS) combined with
separation techniques such as Liquid Chromatography (LC) and/
or Gas Chromatography (GC). Sreekumar et al. carried out
untargeted metabolomic profiling for prostate cancer using LC/
GC-MS across three different types of clinical samples (urine,
plasma and tissue). Over 1,000 features were detected across the
samples analysed [4]. A six-metabolite profile was suggested to
signify high risk of cancer progression and additional isotope
dilution GC-MS analysis identified sarcosine as a potential urinary
biomarker for aggressive prostate cancer. Disappointingly, sarco-
sine as a (urinary or plasma) biomarker in prostate cancer has not
been supported by several independent studies subsequently [5–
15]. In addition, only a handful of these studies have attempted to
perform untargeted metabolite profiling [6,16,17]. In these
subsequent studies, the use of GC-MS or differential mobility
analysis (DMA)-MS provided even more limited coverage of
metabolites when compared to the study by Sreekumar et al [4].
Hence, there is a real need to develop a robust methodological and
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analytical platform to facilitate future efforts in global profiling of
the metabolome in prostate cancer biomarker discovery [18].
Urine has some advantages for metabolomics studies since it has
a high abundance of metabolites, low content of protein, is
collected non-invasively and requires minimal sample preparation
prior to analysis. Recently, application of high resolution (HR) MS
based urinary metabolomics has gained popularity in the study of
cancer diagnosis and biomarker discovery, especially in combina-
tion with diverse LC techniques. HRMS shows higher coverage of
the metabolite profile than other methods and the ability to
identify potential biomarker compounds [19–24]. The introduc-
tion of Hydrophilic Interaction Liquid Chromatography (HILIC),
where the retention mechanism is orthogonal to that of Reversed
Phase (RP) Liquid Chromatography, offers a suitable separation
platform for the many highly polar metabolites in urine [25]. In a
recent study of bladder and kidney cancer biomarkers [22],
combined multivariate analysis (MVA) and Orthogonal Partial
Least Square-Discriminant Analysis (OPLS-DA) of pooled data
from RP and HILIC LC-HRMS showed 100% accuracy in
segregating cancer and healthy subjects correctly.
Data normalisation is considered an essential but unstandar-
dised step in human urinary analysis [26]. Principal Component
Analysis (PCA) score plots can be rendered completely different
simply depending on the normalisation method used, and the
value of candidate biomarkers can be invalidated by choosing a
‘‘wrong’’ internal component as the reference. The signal/level of
creatinine and total ion current (TIC) are commonly used as
normalisation factors in LC-HRMS based urinary metabolite
profiling studies [4,20,22,24]. Warrack et al introduced a new
normalisation strategy based on the MS Total Useful Signals
(MSTUS) which had encouraging correlation to the data based on
normalisation to urinary osmolality and recommended using at
least two different normalisation methods to ensure statistically
significant changes in metabolite profile [27].
A protocol using a combination of GC-MS and LC-MS to carry
out metabolic profiling of plasma and serum was recently
described [28]. Unlike urine it is not necessary to normalise the
data for blood derived-samples in metabolomics studies. Although
comprehensive protocols using GC-MS and LC-MS to profile the
urinary metabolome have also been reported [29,30] none of them
have discussed or compared normalisation methods to any great
extent. In addition, the metabolite coverage by GC-MS is
necessarily limited to volatile components. The combination of
two orthogonal LC methods for metabolomic profiling has only
been applied during the period since the protocols described in
references 28 and 30. Building on our earlier work [25], we have
further optimised our methodology and analysis pipeline, and
profiled urine samples from patients with prostate cancer and
control urines by LC-HRMS using orthogonal separation
methods. The effect of three different normalisation methods in
data analysis was demonstrated. By using the results of clinical tests
the discriminating ability of metabolomic profiling of urine in
relation prostate cancer was evaluated by using both OPLS-DA
models and specific biomarkers. The study was guided by the
STAndards for the Reporting of Diagnostic accuracy (STARD)
criteria [31] and the evaluation checklist can be found in (File S1).
Materials and Methods
Chemicals and materials
HPLC grade acetonitrile (ACN) was purchased from Fisher
Scientific, UK. HPLC grade water was produced by a Direct-Q 3
Ultrapure Water System from Millipore, UK. AnalaR grade
formic acid (98%) was obtained from BDH-Merck, UK. Ammo-
nium carbonate and ammonium acetate were purchased from
Sigma-Aldrich, UK.
Sample collection
All samples studied were obtained with appropriate written
consent from patients. The collection of samples was approved by
the institutional ethics review board (Joint The Chinese University
of Hong Kong - New Territories East Cluster Clinical Research
Ethics Committee). Details on patient-related clinical information
including prostate cancer parameters are described in Table 1.
Sample preparation
The urine samples were stored at 230uC and thawed at room
temperature before preparation for LC-MS analysis. For analysis
using HILIC conditions, 200 ml of urine was thoroughly mixed
with 800 ml of acetonitrile, followed by centrifugation at 3000
revolutions per minute (RPM) for 5 minutes; 800 ml of supernatant
was then transferred to a LC vial. For the RP conditions 200 ml of
urine was diluted with 800 ml of water in a LC vial. The pooled
sample was prepared by gathering 100 ml of urine from each
sample which was then treated as above.
Measurement of creatinine and osmolality
50 ml of diluted samples and prepared creatinine standard
solutions were thoroughly mixed with 100 ml of creatinine
detection reagent (Enzo Life Sciences, UK) in a 96-well plate
and the absorbance was read at 490 nm by using a Spectra Max
M5 from Molecular Devices. The concentrations of creatinine in
the test samples were calculated using a 7-point calibration curve
in which each point was measured in duplicate. After calibrating
with standard solutions (Vitech Scientific Ltd., UK), freezing-point
depression measurement for each sample was performed with an
osmometer (Advanced Micro, Model 3300) in order to determine
the osmolality.
LC-MS data acquisition
Samples were randomly placed in the autosampler tray and the
LC-MS experiment was performed on an Accela 600 HPLC
system combined with an Exactive (Orbitrap) mass spectrometer
from Thermo Fisher Scientific (Bremen, Germany). A ZIC-
pHILIC column (15064.6 mm, 5 mm) and also an ACE C18-AR
column (15064.6 mm, 5 mm) (HiChrom, Reading UK) were
employed for HILIC and RP separations respectively. The mobile
phases used in HILIC conditions were 20 mM ammonium
carbonate buffer (pH 9.2) and pure ACN Under RP conditions
0.1% v/v formic acid in water and 0.1% v/v formic acid were
used as the mobile phases. The HILIC and RP LC eluting
gradient profiles and the MS parameter settings were described in
our previous study [25]. The selective MS2 fragmentation of
potential biomarkers was carried out by using Collision Induced
Dissociation (CID) at 35 V using a Surveyor HPLC system
combined with a LTQ-Orbitrap mass spectrometer from Thermo
Fisher Scientific (Bremen, Germany).
LC-MS data processing by MZMine 2.10 [32]
The raw data was split into a single ESI positive and negative
data set, and also converted into mzML format by using
ProteoWizard. The procedure and the settings of each step used
in MZMine 2.10 are described in File S2. Here the strategy of
using the data of pooled samples to filter out technical and
unrelated biological variations from the data set was introduced.
The five pooled samples were prepared along with test samples
and they were measured as quality controls (QCs) periodically
Metabolomic Profiling in Prostate Cancer
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throughout the whole LC-MS experiment. One of them was
injected three times and the rest were injected only once, therefore
7 sets of QC data were acquired to assess system stability and to
generate a repeatability filter. The features not presenting in all 7
QC data sets were removed because they were either caused by
the variation of the sample preparation or by the LC-MS system
during the data acquisition. Based on this filtered peak list, the
data for individual test samples were aligned and all features not
matching with the pooled sample peak list were removed. Features
within the QC data set are included only if they are observed in
.75% of the test samples. Finally, the features with a relative
standard deviation (RSD) for peak area less than 25% within the
QCs were used for further data analysis.
Normalisation
For the creatinine or osmolality normalisation method, the peak
area of each feature in a sample was scaled to the creatinine
concentration or osmolality of the sample. For MSTUS method
under each combination of LC condition and ESI mode, the peak
areas of all features which remained through the three filters were
summed up and then were replaced by their percentages of the
total value.
Multivariate/statistical analysis
SIMCA-P 13 (Umetrics, Sweden) was used to carry out all
MVA. Prior to PCA and OPLS-DA, the data were mean-centered
and unit variance (UV) scaled. Pareto scaling was also tried but the
models generated were dominated by a few features with large
normalised values (e.g. creatinine and the dimer of urea). Thus,
considering the fact that in searching for biomarkers all features
are biologically equal and that most of the noise was removed by
the filters, UV scaling was used. P-values were calculated by the
two tail Student t test (Microsoft Office 2010). The ROC test was
performed by IBM SPSS Statistics 21.
Results and Discussion
LC-HRMS method evaluation and validation
Untargeted metabolomic profiling based on two orthogonal LC
separation methods was performed [33]: A ZIC-pHILIC column
Table 1. Clinicopathological characteristics of the tumor patients.
PSA at collection ng/ml DRE at collection GS1 GS2 T N M localized/Locally advanced/metatstatic dx
4.6 2a 3 3 2a 0 0 1
12.3 1 3 3 1c 0 0 1
10.1 1 4 3 1c 0 0 1
39.5 2a 4 3 2a 0 0 1
9 1 3 3 1c 0 0 1
8.8 1 3 3 1c 0 0 1
17.7 1 4 4 1c 0 0 1
6.2 1 4 4 1c 0 0 1
9.6 2c 3 5 2c 0 0 1
11.4 1 3 4 1c 0 0 1
1.48 2c 3 3 3b 0 0 2
8.7 2b 4 4 2b 0 0 1
29.5 2b 3 4 2b 0 0 1
51.6 3 3 3 3 0 0 2
63.3 3 4 5 3b 1 0 2
6.6 1 3 3 1c 0 0 1
23.6 2 4 4 3b 1 1 3
12.2 1 3 3 1c 0 0 1
9.4 1 3 4 1c 0 0 1
11.8 1 3 5 1c 0 0 1
52.2 4 4 5 4 0 0 2
35.5 3 3 5 3b 0 0 2
38 2a 4 3 2a 0 0 1
11.4 2a 3 4 2a 0 0 1
54.8 2c 3 4 3b 1 0 2
44.4 2b 4 3 2b 0 0 1
8.2 1 3 3 1c 0 0 2
413 3 5 4 3 0 1 3
32.1 3 3 4 3a 0 0 2
25.5 2b 3 4 3b 0 0 2
GS=Gleason Score T=T stages N=N stages M=M stages.
doi:10.1371/journal.pone.0065880.t001
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with a mobile phase pH at 9.2 for the HILIC method and an ACE
C18-AR column with a mobile phase pH at 2.6 for the RP
method, referred hereafter as ‘‘ZIC-pHILIC’’ and ‘‘RP’’ respec-
tively. In order to examine the complementarity of these two
orthogonal LC methods some standard metabolites were mea-
sured along with the samples under each LC condition. As shown
in our previous study alanine and b-alanine can be separated
under ZIC-pHILIC conditions [25]. Here a clear separation of the
isomers sarcosine, which was previously suggested as prostate
cancer marker, alanine and b-alanine was also achieved under
ZIC-pHILIC conditions but they all eluted at the column dead
volume under RP conditions (Figure S1 and S2 in File S3). The
LC-HRMS raw data were processed by MZMine 2.10 as
described in the Experimental section. Table 2 shows the number
of features remaining after each filter and their percentages based
on the originally detected features. The pooled sample repeatabil-
ity filter effectively removed more than 75% of detected features,
most of which originated from LC-HRMS system noise and
background signals. The numbers of features were modestly
decreased through the 25% missing filter, which removed
biological compounds which were very variable within the
samples. Through the peak area RSD filter features with large
peak area variations can be removed. Such features are generally
due to low MS responses or poor chromatographic peak shapes.
Approximately 5,200 features in total survived these three filters
and were pooled together as a holistic dataset for multivariate and
statistical analysis.
The stability of the LC-HRMS system was verified by
comparing the accurate masses (63 ppm) and retention times
(60.5 min) of compounds present in the urine against authentic
standards: 42 and 51 features were matched to the standards
under ZIC-pHILIC conditions in ESI positive and negative modes
respectively, and 39 and 34 features were assigned under RP
conditions. The system stability was monitored with respect to
variation in retention time, peak area and mass accuracy of these
identified metabolites in 7 QC samples under each LC-HRMS
condition (File S3). After MZMine processing, most of the
standard matched metabolites present in the samples showed
extremely low RSDs for mass accuracy (,1 ppm) and retention
time (,1%). Only few of them showed large variations for peak
area (.25%) because of their low MS responses; these were
excluded by the 25% RSD filter. Having developed the data
filtering methodology these filters were then applied to the data
from the 30 patient and 30 control samples. The features
remaining after applying the filters were then further processed.
Normalisation and multivariate/statistical analysis
There is currently no consensus on normalisation method(s) in
urine metabolomics studies. We applied three independent
normalisation methods and the corresponding PCA score plots
are shown in Figure 1. Given the diversity in life style between
subjects, unsupervised MVA did not separate the samples from the
cancer and control groups. In addition no similarity could be
observed between the pattern structures which is reflected by the
completely different directions and distances (vectors) based on
one sample (shaped as diamond) referenced to three other samples
(shaped as 4-point star, 5-point star and inverted triangle) in each
pattern. The sum of the first and the second principal components
is less than 30% for each model reflecting the poor correlation
among the variables (features) in the dataset. Importantly, in all
four PCA models, the 7 QC features (in green) are close each other
as a cluster in the middle of the pattern, further confirming
excellent system stability throughout. As a supervised MVA
method, OPLS-DA was able to separate study groups according to
predefined biological criteria [22,34]. In this study as the test set 5
cancer subjects including 3 at early stage (T1N0M0) and 5 controls
were taken out from each group .The OPLS-DA models were
built up by using the remaining 25 prostate cancer and control
samples as a training set using data normalised using the three
different normalisation methods and un-normalised data. Figure 2
shows the discrimination of the training set and the prediction of
the test set obtained by applying OPLC-DA to the un-normalised
data and data normalised using three different methods. Very
clear separations between two groups were achieved for the
training set in the models generated with data following
normalisation to creatinine and MSTUS. Only one cancer and
one control sample crossed over the separation line in the model
generated with the osmolality method and raw data. The value of
R2Y(cum), which explains the discriminative power of the OPLS-
DA model, is more than 0.9 with creatinine and MSTUS
normalisation and 0.8 with osmolality normalisation but less than
0.7 with un-normalised data. The value of Q2Y(cum), which is
calculated by 7-folder cross-validation and able to indicate the
predictive power of the model, is about 0.3 for all the methods.
Although this value is not as high as expected (.0.5) all the
samples in the test set were correctly predicted for all three
normalisation methods except one in the MSTUS based model. It
is interesting to note that unlike PCA models the OPLS-DA
models with different normalisation factors show similar pattern
structures and this even the case with non-normalised data. The
vectors from the same sample to the other three are quite similar
in every OPLS-DA model (Figure 2). Based on the above
observations it seems that the normalisation strategy greatly affects
the outcome of the unsupervised MVA but not the supervised.
However, by removing the deviation of metabolite concentration
introduced by urine volume variation, normalisation improves the
performance of supervised MVA. The value of Variable Impor-
tance for the Projection (VIP) indicates the impact factor of the
variable to the model. Generally a variable is regarded important
to the model if its VIP value is .1. Overall 406 unique features
with VIP values .2 were selected from all three OPLS-DA
models. It was found that 76 were common in all three models, 89
Table 2. The numbers of remaining features and their percentages after each data filter.
LC conditions and ESI modes
Originally detected in all
samples After PS filter After 25% missing filter After 25% RSD filter (Final)
ZIC-pHILIC-Pos 7910 (100%) 1839 (23.25%) 1559 (19.71%) 1341 (16.95%)
ZIC-pHILIC-Neg 13254 (100%) 3327 (25.10%) 2875 (21.69%) 1676 (12.65%)
RP-Pos 6697 (100%) 1460 (21.80%) 1233 (18.41%) 1022 (15.26%)
RP-Neg 9264 (100%) 1691 (18.25%) 1416 (15.28%) 1209 (13.05%)
doi:10.1371/journal.pone.0065880.t002
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were in any two models and 241 were from only one model (Figure
S1 in File S4). Those features common in three models showed the
highest average VIP values in comparison to the ones common in
two or only in one model and they included 80% of top 10 features
in VIP value from each model and the remaining 20% could be
found in the group which was common in two models. As
recommended by Warrack et al [27] in order to ensure the
reliability of the biomarkers we focused on the VIP features which
were common in three normalisation methods. This group
included many features which showed the same m/z values under
different LC conditions or were detected in both positive and
negative ion modes with the same retention time. This observation
suggests that these features could be assigned to single metabolites
which would make them more reliable as genuine biomarkers.
Unpaired Student t and ROC tests were performed for these
features across all samples and the calculated P-values and area
under curve (AUC) obtained by ROC are shown in Table S1 in
File S4. As expected all of them showed high AUC (.0.63) and
low P-values (,0.05) and their ratios between the cancer and
control samples are also very similar each other under different
LC-HRMS conditions with different normalisation methods which
supports the reliability of the results. Some other features could
also be considered as potential biomarkers because of significant
statistical results although they were only present in a single LC-
HRMS condition. The discriminative ability of sarcosine for
prostate cancer was also evaluated (Table S1 in File S3); in keeping
with several earlier reports, we found no significant difference in
the sarcosine level between cancer and control groups [6,8–
10,12,15].
Identification of a potential biomarker panel
All the features used in MVA were searched by accurate mass
with a 3 ppm tolerance window against an in-house metabolite
library [25]. 1673 and 1159 features were putatively identified as
metabolites or related signals under ZIC-pHILIC and RP
conditions respectively. The identification results in Excel format
can be downloaded from our website: http://www.metabolomics.
strath.ac.uk and people wishing to file share raw data are welcome
to contact us. The biomarkers in File S4 were successfully assigned
to genuine metabolites but some of them with several isomers. In
order to finalize the identity of the biomarkers an MS2 experiment
was carried out. A feature mentioned in Table S1 in File S4
(145.062 m/z in ESI negative and 147.076 m/z in ESI positive
mode) was assigned the formula C5H10N2O3 with mass error less
than 1 ppm. Three isomers can be assigned to this formula in the
HMDB. These are glutamine, ureido isobutyric acid and
alanylglycine. As can been seen in figure 3A the interesting
feature refers to Peak B in the extracted ion chromatograms. By
MS2 analysis Peaks A and C showed the same fragmentation
pattern which can be explained as shown in figure 3B and were
identified as glutamine by comparing with a standard MS/MS
spectrum in the HMDB. Peak B showed a completely different
fragmentation pattern and corresponds to ureido isobutyric acid
from the interpretation of the MS2 spectra. No standard MS/MS
spectrum was found in any public database. The fragmentation
seems to be directed by the ureido group in the molecule
(figure 3B). The absence of a free amine group reduces the polarity
of the molecule which explains the opposite elution order to that of
glutamine under the two orthogonal LC conditions (figure 3A).
Finally by checking the raw data Peak A was identified as being
Figure 1. PCA score plots with different normalisation methods. Cancer subjects are labelled in red, controls in blue and QCs in green. The
vector from diamond to 5-point star is labelled in black, to 4-point star in green and to inverted triangle in purple. (A–C) Normalisation to creatinine,
MSTUS and osmolality respectively. (D) raw data without normalisation.
doi:10.1371/journal.pone.0065880.g001
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due to an in-source fragment of alpha-N-phenylacetyl-L-glutamine
which is a highly abundant component in human urine.
Alanylglycine might correspond to the tiny peak before and after
Peak B under ZIC-pHILIC and RP conditions respectively.
However, its signal at MS level 1 was too weak to obtain reliable
MS2 fragmentation. The final potential biomarkers and their
identities, including MS2 fragmentation data, are shown in File S5.
More potential biomarkers were identified under the ZIC-pHILIC
conditions than under RP conditions. It was interesting to note
that there were some biomarkers identified from food e.g.
stachydrine and 3-hydroxystachydrine. Their reliability/authen-
ticity as biomarkers was naturally suspected.
From our literature review for cancer diagnosis by metabolo-
mics no studies have assessed the discriminative ability of proposed
biomarkers in a single paper by testing samples collected
completely independently of the original study. We carried out
analysis on urine samples obtained from 30 additional prostate
cancer patients and compared data against the control samples
analysed earlier. Based on the optimal methodology identified
above these 60 samples were compared only under ZIC-pHILIC
conditions and the data was normalised against creatinine
concentration. In the comparison between the controls and the
independently collected prostate cancer samples 14 out of 33
biomarkers were below the 0.05 P-value threshold including
ureido isobutyric acid which had almost identical statistical results
in both ES1 positive and negative modes (Table 3). Some of the
food metabolites did not show significant difference between
cancer and healthy groups. Four out of 14 validated biomarkers
were identified with confidence as ureido isobutyric acid,
indolylacryloyglycine, acetylvanilalinine and 2-oxoglutarate all of
which have not been reported in the previous metabolite profiling
studies for prostate cancer.
Based on the total 90 subjects (60 cancer v.s. 30 controls) the
diagnostic power for prostate cancer was evaluated by an ROC
test for each of them as well as for their combined power. The
peak area was UV scaled and if the level of the biomarker was
higher in the cancer group than in the healthy group, it would be
treated as positive influence and lower as negative influence. The
generated AUC value for the combined biomarkers was 0.896 and
the sensitivity and specificity were also improved at the best cut-off
point compared to other single biomarkers (Figure 4. The
diagnostic efficacy could be improved further by including more
single biomarkers but due to their putative identification they were
not included in the combination. Overall, the use of the combined
biomarker panel is comparable to the use of PSA testing (AUC at
0.94). With future refinement, such a panel may be of clinical use
either in isolation or in combination with PSA itself. Due to the
limitation of number of subjects measured in this study and the
uncertainty of the significance of a few significant biomarkers
selected from over a thousand features, further validation of the
panel and the specific biomarkers will be performed with more
subjects and the data will be publically accessible on our website:
http://www.metabolomics.strath.ac.uk.
The four identified biomarkers are not linked in an obvious way
although individually they have some interesting biochemical
background as biomarkers of other medical conditions. Ureidoi-
sobutyric acid (UIBA) is well established as a urinary marker of an
inborn error of metabolism due to ureidopropionase deficiency
Figure 2. OPLS-DA score plot with different normalisation methods. Cancer subjects are shaped as squares and controls as circles. The
training set is labelled in filled red and the test set in hollowed blue. The four selected subjects and the vectors are same shaped and coloured as
Figure 1.
doi:10.1371/journal.pone.0065880.g002
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where its levels are elevated [35]. In the current case its levels are
lower in subjects with prostate cancer. UIBA is a metabolite of the
DNA base thymidine. UIBA is also a DNA degradation product
derived from oxidative damage of thymidine and such damaged
bases are removed from DNA by the repair enzyme DNA
glycosylase [36–38]. Failure to remove such residues can result in
mutations being formed during replication due to incorrect base
pairing with the damaged site. Lower levels of UIBA might point
to reduced rates of excision repair.
Indoylacroylglycine (IAG) has been proposed as a marker for
autism in children. Its origin is unclear although it has been
proposed that it is produced by metabolic transformation of
tryptophan by gut microflora. However, it has been established
that its levels fluctuate in human urine according to the time of
year and higher levels may relate to increased exposure to UV
light. In this respect it is analogous to urocanic acid which is
produced from histidine in response to UV radiation [39].
N-acetylvanilalinine (AVA) has been monitored in urine for the
detection of a rare inborn error of metabolism due to aromatic
amino acid decarboxylase (AAD) deficiency [40]. In the group of
biomarkers presented in table 3 there is an unidentified marker
(268.083 m/z, negative mode), which like AVA is highly elevated
in prostate cancer patients. This marker differs in elemental
Figure 3. LC-HRMS/MS results of isomers of C5H10N2O3. Extracted ion chromatograms under 4 different LC-HRMS conditions (A) and the
interpretation of their MS2 fragmentations (B).
doi:10.1371/journal.pone.0065880.g003
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composition by one oxygen atom from AVA suggesting it might be
hydroxylated AVA.
Conclusions
The current study has established a simple robust protocol for
screening of urine for biomarkers by using orthogonal LC methods
in conjunction with HRMS. A data extraction protocol based on
MZmine was established to remove technical and biologically non-
related variations. Applying the developed method we successfully
performed a preliminary study on urinary metabolomics for
diagnosis of prostate cancer and biomarker discovery. In
comparison with previous studies much more comprehensive
metabolite profiling was achieved by employing two orthogonal
LC methods combined with HRMS which provided a greater
opportunity to uncover more potential biomarkers. The lower
effect of different normalisation methods on supervised MVA
models (OPLS-DA) than on unsupervised (PCA) models was
reported for the first time. In addition, a clear improvement in
Table 3. The statistical results for biomarkers surviving testing against a new cohort of patients.
Polarity m/z Rt Name Formula P-value Ratio
N 268.083 13.47 Unknownc C12H15NO6 ,0.0001 4.66
P 236.149 11.51 Unknownc C14H9N2O2 ,0.0001 0.37
P 240.102 8.24 N-hydroxy-2-acetamidofluoreneb C15H13NO2 0.0003 0.13
N 243.078 6.74 indolylacryloyglycinea C13H12N2O3 0.0007 2.58
N 145.062 11.66 Ureidoisobutyric acida C5H10N2O3 0.0014 0.54
N 210.026 5.00 Unknown 0.0016 0.30
N 172.025 15.20 Unknownc C6H7NO5 0.0020 2.47
N 252.088 5.01 acetylvanilalininea C12H15NO5 0.0022 3.94
N 258.992 16.48 Caffeic acid sulfatea C9H8O7S 0.0026 2.29
P 147.077 11.66 Ureidoisobutyric acida C5H10N2O3 0.0030 0.57
N 401.182 6.40 Thr-Trp-Prob C20H26N4O5 0.0041 0.49
N 145.014 15.52 2-oxoglutaratea C5H6O5 0.0067 1.97
N 275.023 13.21 Dihydro ferulic acid sulphateb C10H12SO7 0.0332 0.23
P 169.061 7.77 2,3-diaminosalicylic acida C7H8N2O3 0.0462 2.19
a: identified by accurate mass and MS2 fragmentation.
b: only identified by accurate mass in the in-house database.
c: only elemental composition predicted formula (,3 ppm).
doi:10.1371/journal.pone.0065880.t003
Figure 4. ROC testing results of validated biomarker (UIBA) and the combined biomarker.
doi:10.1371/journal.pone.0065880.g004
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discriminative ability for prostate cancer with normalised data in
OPLS-DA models proves the necessity of normalisation. The
complete discrimination of men with prostate cancer could be
achieved in OPLS-DA models with sensible accuracy of prediction
on a test set. The new biomarkers included UIBA which was
identified under all LC-HRMS conditions and survived through
the validation test of using a new cohort of patients from a
different geographic region. The diagnostic ability obtained by
combining the validated biomarkers was close to the level of the
PSA test. Further validation experiments will be carried in our lab
including with more detailed clinical and pathological testing and
the testing of further groups of subjects to prove the utility of the
biomarkers found in the current study. We hope that other groups
pursuing similar protocols aimed at diagnosis of prostate cancer
will be able to test the candidate biomarkers we have described
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